Table 5.

Univariate analysis of DFS and OS in HER2-overexpressed patients

Factors	DFS HR				OS HR
	Average	Lower	Upper	P-value	Average	Lower	Upper	P-value
Age	1.02	0.96	1.09	0.445	1.04	0.98	1.11	0.195
T stage	2.75	2.75	0.73	0.134	1.77	0.41	7.62	0.441
N stage	3.54	1.12	11.22	0.032	3.17	1.00	10.06	0.050
ER	1.87	0.47	7.47	0.377	0.93	0.23	3.72	0.920
TAM	1.05	0.22	5.05	0.953	0.81	0.22	2.96	0.754
Other endoa	2.50	0.63	10.01	0.194	1.24	0.31	4.96	0.761
Chemotherapy	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GPER1	4.47	0.926	21.56	0.062	3.56	0.72	17.65	0.12

Note:

^aOther endo: other endocrine therapy except for TAM.

Abbreviations: DFS, disease-free survival; ER, estrogen receptor; GPER1, G protein-coupled estrogen receptor 1; HR, hazard ratio; N/A, not available; OS, overall survival; TAM, tamoxifen treatment.